Ms. Flowers joined Kura as Chief Commercial Officer in January 2020, bringing extensive commercial experience leading top-performing oncology product launches at large pharmaceutical and biotechnology organizations. Most recently, she served as Senior Vice President, Commercial Operations at Array Biopharma, where she built and led the commercial organization that delivered the successful launch of Braftovi® + Mektovi® for patients with BRAF-mutant melanoma in the U.S. Previously, she held various commercial leadership roles at Pfizer, including serving as the U.S. commercial lead for the launch of the blockbuster drug IBRANCE® in breast cancer and for the launch of INLYTA® in renal cell carcinoma. She began her career at Procter & Gamble Pharmaceuticals. Ms. Flowers currently serves on the board of directors of ReForm Biologics, a private life sciences company, and PMV Pharmaceuticals, Inc. (Nasdaq: PMVP). Ms. Flowers earned her MBA from Harvard Business School and her BS in Molecular & Cellular Biology and Psychology from the University of Arizona.